Last reviewed · How we verify

NCT07160036: AO-SLO

Repeatability of AO-SLO (Mona IIa) Technology and Cone Cell Density of Individuals Use Repeated Low-level Red-light Therapy

Recruiting now NA Last updated 15 September 2025
What this trial tests

NA trial testing RLRL(Model RS-200-2A, Eyerising; Suzhou Xuanjia Optoelectronic Technology Co., Ltd., Suzhou, China)) in Myopia in 180 participants. Currently enrolling.

Timeline
20 September 2025
Primary endpoint
20 November 2025
20 December 2025

Quick facts

Lead sponsorRuihua Wei
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment180
Start date20 September 2025
Primary completion20 November 2025
Estimated completion20 December 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Ruihua Wei — full company profile →

Who can join

Adults 6 to 55, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the repeatability of AO-SLO (Mona IIa) technology and the difference of cone cell density between individuals who used or not used repeated low-intensity red light treatment

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Ruihua Wei trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07160036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing